NasdaqGM:STAAMedical Equipment
A Look At STAAR Surgical (STAA) Valuation After FDA Expands EVO ICL Age Range
STAAR Surgical (STAA) is back in focus after the U.S. FDA approved an expanded age indication for its EVO and EVO+ Visian Implantable Collamer Lenses, lifting the upper limit from 45 to 60 years.
See our latest analysis for STAAR Surgical.
The FDA age expansion comes as STAAR Surgical’s 7 day share price return of 12.58% contrasts with a 90 day share price decline of 24.15% and a 3 year total shareholder return decline of 65.58%, suggesting recent momentum after a tough longer stretch.
If...